The global AI in clinical trials market size is estimated to be valued at USD 1.77 Billion in 2025. It can reach a valuation of USD 5.12 Billion by 2032, by exhibiting a CAGR of 16.4% throughout the forecast period (2025-2032).
The market growth is driven by the immense demand for the discovery of new drugs, emergence of new chronic diseases, and lack of participants in clinical trials. The use of existing patient datasets for matching with ongoing clinical trials presents a viable market opportunity.
However, the lack of common data standards for the synthesis of patient data using AI can limit the market growth.
Key Market Insights
The AI in clinical trials market is likely to be shaped by patient-centric trial design and the testing of protocol design in silico.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/ai-in-clinical-trials-market
AI in Clinical Trials Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 1.77 Billion |
|
Estimated Value by 2032 |
USD 5.12 Billion |
|
Growth Rate |
16.4% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The delays in clinical trials can drive the demand for the AI in clinical trials market. The soaring costs of clinical trials, amid a surge in chronic and autoimmune diseases, can also drive the integration of AI into clinical workflows. Its use can extend from the careful selection of patient size to the implementation of targeted outreach programs, ensuring patient engagement in future trials.
For instance, the National Institute of Health, a U.S. agency responsible for biomedical research, developed an AI algorithm, TrialGPT, on November 18, 2024. The algorithm could help researchers match participants to clinical trials by providing an accurate summary of its reasoning. This can expedite participant enrollment numbers and accelerate clinical research.
The human-in-the-loop (HITL) approach, which involves supervising AI recommendations and making adjustments as needed, can drive growth in the AI in clinical trials market. This creates transparency in the process and reduces bias in AI-driven decisions.
Market Opportunity: Digital Twins for Patient Simulations
The utilization of digital twins for testing protocol designs in silico can save time for researchers and lower the cost of clinical trials. In silico implies the use of virtual patient simulations and their response to treatments over time. This helps sponsors understand the efficacy of treatments and increase their power over time. The outline of guidelines by regulatory agencies, such as the U.S. Food & Drug Administration (FDA) on the use of AI and digital twins in drug development can work in the favor of major players. This can accelerate drug development and reduce the reliance on traditional control groups.
Market Challenge: Investigator-initiated Clinical Trial
The onboarding of investigators in ongoing clinical trials leads to delays and poses a major challenge to market growth. The budgeting and contracting of investigators, as well as any amendments to existing contracts, can increase the trial's costs. However, an AI-enabled contract lifecycle management software can help streamline the entire process.
Analyst’s View
Recent Developments
Lunit, a South Korea-based provider of AI for cancer research, announced the launch of AI in clinical trials under its partnership agreement with CellCarta on September 24, 2025. The AI-powered analysis can glean valuable insights within clinical trials and fuel precise drug development in cancer research.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :